New hope for hard-to-treat leukemia: early trial combines chemo with donor cells before transplant
NCT ID NCT07297173
First seen Jan 11, 2026 · Last updated May 18, 2026 · Updated 20 times
Summary
This early-phase study is for people with relapsed or refractory leukemia, meaning their cancer has returned or not responded to standard treatments. The approach combines chemotherapy with an infusion of immune cells from a partially matched donor, given as a bridge to a stem cell transplant. The main goals are to check safety, side effects (like graft-versus-host disease and infections), and how well it works. Only 5 participants will be enrolled in this first step.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, 100071, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.